Hwk-007
Hereditary Thrombophilia Due To Congenital Protein C Deficiency
Whitehawk Therapeutics, Inc.antibody_drug_conjugatePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
1 Active assets in the Hereditary Thrombophilia Due To Congenital Protein C Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hwk-016, Mucin-16-Targeted Adc Whitehawk Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Hwk-007 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →